Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...

March 11, 2025 -- The FDA has approved a new treatment for children with generalized myasthenia gravis (gMG), a disease ... damage and help relieve symptoms. First approved in 2007, the drug ...

Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including ... "This is not only because the symptoms are different from patient to patient ...

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

The first group is treatments that just help with the symptoms of the disease ... We do know that myasthenia gravis is an autoimmune condition. So there's an autoimmune response that's directed ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

On World Rare Diseases Day, read on to learn more about Myasthenia Gravis, a complex autoimmune disorder that requires careful management. Early diagnosis and appropriate treatment can help ...

Supplementary treatment with radiation and cytostatic ... No writing assistance was utilized in the production of this manuscript. Myasthenia gravis (MG) should be subgrouped into early-onset ...